Zymeworks (ZYME) Reports Phase 1 Trial Results for Ovarian Cancer Drug

Zymeworks (ZYME) recently reported results from its Phase 1 trial for an ovarian cancer drug. The trial aims to assess the drug's safety and efficacy in treating patients with this condition. Specific data points, including patient response rates and side effects, are crucial for determining the drug's viability in the market. Positive results could influence investor sentiment and impact Zymeworks' stock performance in future trading sessions.